generation bio is creating a revolutionary new class of genetic medicines that deliver durable, high levels of gene expression and have drug-like properties, including ability to titrate to effect and re-dose. our unique genewave technology allows us to overcome the limitations of other approaches by delivering larger genes, including more sophisticated regulatory elements, and avoiding the immunogenicity which limits both the number of patients who can be treated and the ability to re-dose them over time. we are a community of creative problem-solvers and independent thinkers. we are guided by strong personal integrity, humility, and the collaborative, learning mindset required to create solutions for patients and their families. to learn more about our efforts to usher in a new generation in medicine, please visit www.generationbio.com or our twitter feed, @lifetimegenetx.
Company profile
Ticker
GBIO
Exchange
Website
CEO
Cameron Geoffrey McDonough
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Generation Bio Securities Corporation ...
IRS number
814301281
GBIO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
8-K
Termination of a Material Definitive Agreement
2 Feb 24
8-K
Other Events
8 Jan 24
8-K
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
29 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Latest ownership filings
4
Matthew Stanton
17 Apr 24
4
Phillip Samayoa
17 Apr 24
4
Antoinette Paone
17 Apr 24
4
Matthew Norkunas
17 Apr 24
4
GEOFF MCDONOUGH
17 Apr 24
4
Yalonda Howze
17 Apr 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
Atlas Venture Fund X, L.P.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 99.05 mm | 99.05 mm | 99.05 mm | 99.05 mm | 99.05 mm | 99.05 mm |
Cash burn (monthly) | 17.20 mm | 3.43 mm | 10.45 mm | 11.24 mm | 8.30 mm | 4.23 mm |
Cash used (since last report) | 118.82 mm | 23.67 mm | 72.19 mm | 77.61 mm | 57.32 mm | 29.22 mm |
Cash remaining | -19.77 mm | 75.38 mm | 26.86 mm | 21.45 mm | 41.73 mm | 69.83 mm |
Runway (months of cash) | -1.1 | 22.0 | 2.6 | 1.9 | 5.0 | 16.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 86 |
Opened positions | 10 |
Closed positions | 13 |
Increased positions | 29 |
Reduced positions | 25 |
13F shares | Current |
---|---|
Total value | 295.12 bn |
Total shares | 77.85 mm |
Total puts | 5.40 k |
Total calls | 1.00 k |
Total put/call ratio | 5.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 8.62 mm | $47.42 bn |
Atlas Venture Life Science Advisors | 8.28 mm | $45.54 bn |
T. Rowe Price | 7.49 mm | $41.24 bn |
Atlas Venture Fund X | 7.11 mm | $50.35 mm |
ModernaTX | 5.86 mm | $0.00 |
BLVGF Bellevue | 3.62 mm | $19.91 bn |
BBBOF BB Biotech | 3.61 mm | $0.00 |
BLK Blackrock | 3.54 mm | $19.45 bn |
T. Rowe Price Investment Management | 3.51 mm | $19.32 bn |
Artal | 2.81 mm | $15.48 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Matthew Stanton | Common Stock | Payment of exercise | Dispose F | No | No | 3.7 | 492 | 1.82 k | 244,955 |
15 Apr 24 | Matthew Stanton | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,674 | 0.00 | 245,447 |
15 Apr 24 | Matthew Stanton | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,674 | 0.00 | 18,407 |
15 Apr 24 | Phillip Samayoa | Common Stock | Payment of exercise | Dispose F | No | No | 3.7 | 337 | 1.25 k | 113,758 |
15 Apr 24 | Phillip Samayoa | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,147 | 0.00 | 114,095 |
15 Apr 24 | Phillip Samayoa | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,147 | 0.00 | 12,611 |
15 Apr 24 | Antoinette Paone | Common Stock | Payment of exercise | Dispose F | No | No | 3.7 | 468 | 1.73 k | 13,807 |
15 Apr 24 | Antoinette Paone | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,592 | 0.00 | 14,275 |
15 Apr 24 | Antoinette Paone | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,592 | 0.00 | 17,508 |
15 Apr 24 | Yalonda Howze | Common Stock | Payment of exercise | Dispose F | No | No | 3.7 | 3,930 | 14.54 k | 9,458 |
News
Needham Reiterates Buy on Generation Bio, Maintains $10 Price Target
10 Apr 24
Wedbush Reiterates Outperform on Generation Bio, Maintains $5 Price Target
7 Mar 24
Needham Maintains Buy on Generation Bio, Lowers Price Target to $10
7 Mar 24
Generation Bio Q4 EPS $(0.53) Misses $(0.45) Estimate
6 Mar 24
Press releases
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
22 Apr 24
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Thinking about buying stock in CureVac, Quantum-Si, Clearone, Rambus, or Generation Bio?
12 Mar 24
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
27 Feb 24